Effect of Temperature of Incubation on Activation of Brain-Pro thoracic Gland System of Diapausing Pupae in Samia cynthia pryeri

Termination of diapause occurs with activation of brain-prothoracic gland system in diapausing pupae of Samia cynthia pryeri. It does not occur with 20℃ incubation, but it occurs with 26℃ incubation. To investigate the cause of this fact histological change of neurosecretory cells of pupal brain during incubation and effect of β-ecdysone injection were observed. In histological observation, phloxinophilic granules of lateral B type cells in pars intercerebralis decreased on and after the 5-th day of 20℃ incubation. Diapausing pupae developed into imagines with β-ecdysone injection during 20℃ incubation. From these results, it is concluded that fail of termination of diapause with 20℃ incubation is not resulted from the inactive state of neurosecretory cells in brain but it is resulted from the inactive state of ecdysone secretory system in this temperature.Article信州大学理学部紀要 21(2): 105-114(1987)departmental bulletin pape

Thermal neutron flux evaluation by a single crystal CVD diamond detector in LHD deuterium experiment

The single crystal CVD diamond detector (SDD) was installed in the torus hall of the Large Helical Device (LHD) to measure neutrons with high time resolution and neutron energy resolution. The LiF foil with 95.62 % of 6Li isotope enrichment pasted on the detector was used as the thermal neutron convertor as the energetic ions of 2.0 MeV alpha and 2.7 MeV triton particles generated in LiF foil and deposited the energy into SDD. SDD were exposed to the neutron field in the torus hall of the LHD during the 2nd campaign of the deuterium experiment. The total pulse height in SDD was linearly propotional to the neutron yield in a plasma operation in LHD over 4 orders of magnitude. The energetic alpha and triton were separately measured by SDD with LiF with the thickness of 1.9 μm, although SDD with LiF with the thickness of 350 μm showed a broadened peak due to the large energy loss of energetic particles generated in the bulk of LiF. The modeling with MCNP and PHITS codes well interpreted the pulse height spectra for SDD with LiF with different thicknesses. The results above demonstrated the sufficient time resolution and energy discrimination of SDD used in this work

Safety and pharmacokinetics of recombinant human hepatocyte growth factor (rh-HGF) in patients with fulminant hepatitis: a phase I/II clinical trial, following preclinical studies to ensure safety

<p>Abstract</p> <p>Background</p> <p>Hepatocyte growth factor (HGF) stimulates hepatocyte proliferation, and also acts as an anti-apoptotic factor. Therefore, HGF is a potential therapeutic agent for treatment of fatal liver diseases. We performed a translational medicine protocol with recombinant human HGF (rh-HGF), including a phase I/II study of patients with fulminant hepatitis (FH) or late-onset hepatic failure (LOHF), in order to examine the safety, pharmacokinetics, and clinical efficacy of this molecule.</p> <p>Methods</p> <p>Potential adverse effects identified through preclinical safety tests with rh-HGF include a decrease in blood pressure (BP) and an increase in urinary excretion of albumin. Therefore, we further investigated the effect of rh-HGF on circulatory status and renal toxicity in preclinical animal studies. In a clinical trial, 20 patients with FH or LOHF were evaluated for participation in this clinical trial, and four patients were enrolled. Subjects received rh-HGF (0.6 mg/m²/day) intravenously for 12 to 14 days.</p> <p>Results</p> <p>We established an infusion method to avoid rapid BP reduction in miniature swine, and confirmed reversibility of renal toxicity in rats. Although administration of rh-HGF moderately decreased BP in the participating subjects, this BP reduction did not require cessation of rh-HGF or any vasopressor therapy; BP returned to resting levels after the completion of rh-HGF infusion. Repeated doses of rh-HGF did not induce renal toxicity, and severe adverse events were not observed. Two patients survived, however, there was no evidence that rh-HGF was effective for the treatment of FH or LOHF.</p> <p>Conclusions</p> <p>Intravenous rh-HGF at a dose of 0.6 mg/m²was well tolerated in patients with FH or LOHF; therefore, it is desirable to conduct further investigations to determine the efficacy of rh-HGF at an increased dose.</p